



## Correction to: Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis

Massimo Tempestilli<sup>1</sup> · Giulia Valeria Stazi<sup>1</sup> · Gaetano Maffongelli<sup>1</sup> · Maria Cristina Marini<sup>1</sup> · Tommaso Ascoli Bartoli<sup>1</sup> · Giuseppe Ippolito<sup>1</sup> · Emanuele Nicastri<sup>1</sup> · Luisa Marchioni<sup>1</sup> · Chiara Agrati<sup>1</sup>

Published online: 3 March 2022  
© Springer-Verlag GmbH Germany, part of Springer Nature 2022

**Correction to:** European Journal of Clinical Pharmacology (2021) 77:1583–1585  
<https://doi.org/10.1007/s00228-021-03128-7>

In the Acknowledgments section there is a typing error in the code number of the project is COVID-2020–12371675.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

The original article can be found online at <https://doi.org/10.1007/s00228-021-03128-7>.

---

✉ Chiara Agrati  
chiara.agrati@inmi.it

<sup>1</sup> Immunology and Pharmacology Laboratory, National Institute for Infectious Diseases “Lazzaro Spallanzani”, IRCCS, via Portuense, 292, 00149 Rome, Italy